Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Klinman Website

Dennis M. Klinman, M.D., Ph.D.

Selected Publications

1)  Gursel M, Klinman D.
Use of CpG Oligonucleotides as Mucosal Adjuvants. In: Mucosal Immunology. Volume Chapter 62.
Elsevier Inc.; 2014. In Press. [Book Chapter]
2)  Shimada M, Yoshizaki S, Ichino M, Klinman DM, Okuda K.
Apoptosis of antigen-specific CTLs contributes to low immune response in gut-associated lymphoid tissue post vaccination.
Vaccine. [Epub ahead of print], 2014.
[Journal]
3)  Scheiermann J, Klinman DM.
Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer.
Vaccine. [Epub ahead of print], 2014.
[Journal]
4)  Zhao BG, Vasilakos JP, Tross D, Smirnov D, Klinman DM.
Combination therapy targeting toll like receptors 7, 8 and 9 eliminates large established tumors.
J Immunother Cancer. 2: 12, 2014.
[Journal]
5)  Hodge DL, Berthet C, Coppola V, Kastenmüller W, Buschman MD, Schaughency PM, Shirota H, Scarzello AJ, Subleski JJ, Anver MR, Ortaldo JR, Lin F, Reynolds DA, Sanford ME, Kaldis P, Tessarollo L, Klinman DM, Young HA.
IFN-gamma AU-rich element removal promotes chronic IFN-gamma expression and autoimmunity in mice.
J. Autoimmun. [Epub ahead of print], 2014.
[Journal]
6)  Shirota H, Klinman DM.
Recent progress concerning CpG DNA and its use as a vaccine adjuvant.
Expert Rev Vaccines. 13: 299-312, 2014.
[Journal]
7)  Bode C, Kinjo T, Alvord WG, Klinman DM.
Suppressive oligodeoxynucleotides reduce lung cancer susceptibility in mice with silicosis.
Carcinogenesis. 35: 1078-83, 2014.
[Journal]
8)  Shirota H, Klinman DM.
TLR-9 agonist immunostimulatory sequence adjuvants linked to cancer antigens.
Methods Mol. Biol. 1139: 337-44, 2014.
[Journal]
9)  Sui Y, Hogg A, Wang Y, Frey B, Yu H, Xia Z, Venzon D, McKinnon K, Smedley J, Gathuka M, Klinman D, Keele BF, Langermann S, Liu L, Franchini G, Berzofsky JA.
Vaccine-induced myeloid cell population dampens protective immunity to SIV.
J. Clin. Invest. 124: 2538-49, 2014.
[Journal]
10)  Shi G, Vistica BP, Nugent LF, Tan C, Wawrousek EF, Klinman DM, Gery I.
Differential Involvement of Th1 and Th17 in Pathogenic Autoimmune Processes Triggered by Different TLR Ligands.
J. Immunol. 191: 415-23, 2013.
[Journal]
Click Here to View Expanded Bibliography.

This page was last updated on 8/4/2014.